Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials
Peey‐Sei Kok, Doah Cho, Won-Hee Yoon, et al.
JAMA Network Open (2020) Vol. 3, Iss. 9, pp. e2011809-e2011809
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Immune-related adverse events as potential surrogates of immune checkpoint inhibitors’ efficacy: a systematic review and meta-analysis of randomized studies
Vito Amoroso, F. Gallo, Andrea Alberti, et al.
ESMO Open (2023) Vol. 8, Iss. 2, pp. 100787-100787
Open Access | Times Cited: 36
Proportion of patients in phase 2 oncology trials receiving treatments that are ultimately approved
Charlotte Ouimet, Bertalan Fodor, Joseph C. Del Paggio, et al.
JNCI Journal of the National Cancer Institute (2025)
Closed Access | Times Cited: 1
Multiplex Immunofluorescence and the Digital Image Analysis Workflow for Evaluation of the Tumor Immune Environment in Translational Research
Frank Rojas, Sharia Hernandez, Rossana Lazcano, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 28
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)
Maria Carmela Piccirillo, Quincy Chu, Penelope A. Bradbury, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 6, pp. 813-819
Closed Access | Times Cited: 17
Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC
Amanda J.W. Gibson, Aliyah Pabani, Michelle L. Dean, et al.
JTO Clinical and Research Reports (2023) Vol. 4, Iss. 3, pp. 100460-100460
Open Access | Times Cited: 14
Integrating mitochondrial and lysosomal gene analysis for breast cancer prognosis using machine learning
Huilin Chen, Zhenghui Wang, Jiale Shi, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Optimal early endpoint for second-line or subsequent immune checkpoint inhibitors in previously treated advanced solid cancers: a systematic review
Jingqiu Li, Xiaoding Zhou, Lei Wu, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Monitoring peripheral blood data supports the prediction of immunotherapy response in advanced non-small cell lung cancer based on real-world data
Ana Delia Ramos-Guerra, Benito Farina, Jaime Rubio, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 4
Open Access
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects
Deborah Plana, Geoffrey Fell, Brian M. Alexander, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 20
The validity of progression‐free survival 2 as a surrogate trial end point for overall survival
Rachel Woodford, Deborah Zhou, Peey‐Sei Kok, et al.
Cancer (2022) Vol. 128, Iss. 7, pp. 1449-1457
Closed Access | Times Cited: 16
Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments
Silvia Stacchiotti, Anna Maria Frezza, George D. Demetri, et al.
Cancer Treatment Reviews (2022) Vol. 110, pp. 102455-102455
Open Access | Times Cited: 16
Prognostic impact of LILRB4 expression on tumor‐infiltrating cells in resected non‐small cell lung cancer
Sakiko Kumata, Hirotsugu Notsuda, Mei‐Tzu Su, et al.
Thoracic Cancer (2023) Vol. 14, Iss. 21, pp. 2057-2068
Open Access | Times Cited: 10
A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations
Subotheni Thavaneswaran, Maya Kansara, Frank Cheau‐Feng Lin, et al.
British Journal of Cancer (2023) Vol. 129, Iss. 3, pp. 475-485
Open Access | Times Cited: 10
Assessment of Surrogate End Point Trends in Clinical Trials to Approve Oncology Drugs From 2001 to 2020 in Japan
Hideki Maeda, Riko Shingai, Kentaro Takeda, et al.
JAMA Network Open (2023) Vol. 6, Iss. 4, pp. e238875-e238875
Open Access | Times Cited: 8
Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials
Rachel Woodford, Deborah Zhou, Peey‐Sei Kok, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 2
Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis
Joel Veas Rodríguez, Ana I. Prieto, Ester Vilaprinyó, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 201, pp. 104416-104416
Open Access | Times Cited: 2
Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis
Sarah Goring, N. Varol, Nathalie Waser, et al.
Lung Cancer (2022) Vol. 170, pp. 122-132
Closed Access | Times Cited: 9
Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)
Se Hyun Kim, Seock‐Ah Im, Koung Jin Suh, et al.
European Journal of Cancer (2023) Vol. 195, pp. 113386-113386
Open Access | Times Cited: 5
Time to deterioration of patient-reported outcomes as a surrogate of overall survival: a meta-analysis
Adel Shahnam, Udit Nindra, Jayesh Desai, et al.
JNCI Journal of the National Cancer Institute (2023) Vol. 115, Iss. 12, pp. 1475-1482
Closed Access | Times Cited: 4
Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer
Changhee Park, Koung Jin Suh, Se Hyun Kim, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 10
Open Access | Times Cited: 1
A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non–Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
Badi El Osta, Jennifer W. Carlisle, Conor Steuer, et al.
Clinical Lung Cancer (2022) Vol. 23, Iss. 7, pp. e400-e404
Closed Access | Times Cited: 7
Should Basket Trials Be Pathways to Drug Registration for Biomarker-Defined Subgroups of Advanced Cancers?
Kelvin Chan, Ian F. Tannock
Journal of Clinical Oncology (2021) Vol. 39, Iss. 22, pp. 2426-2429
Open Access | Times Cited: 9
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights
Antonella Cammarota, Valentina Zanuso, Tiziana Pressiani, et al.
Journal of Hepatocellular Carcinoma (2022) Vol. Volume 9, pp. 1011-1027
Open Access | Times Cited: 6
Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival
Alexa R. Weingarden, John Gubatan, Sundeep Singh, et al.
World Journal of Gastroenterology (2022) Vol. 28, Iss. 39, pp. 5750-5763
Open Access | Times Cited: 6
Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myeloma
Patrick Daniele, Carla Mamolo, Joseph C. Cappelleri, et al.
Future Oncology (2023) Vol. 19, Iss. 6, pp. 463-471
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top